Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

NCT00332202 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00332202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00332202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2006
Completion date
July 31, 2013
Enrollment
758 (actual)
Sites
153

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma